Age-related macular degeneration (AMD) prevalence bar graph by sex, race, and ethnicity. US map, shaded by state, shows AMD prevalence, Washington, DC at 3497, Rhode Island at 7214 per 100000. Male vs. Female prevalence shown.

#AgeRelatedMacularDegeneration, #DiabeticRetinopathy, #DiabeticMacularEdema, and #RetinalVeinOcclusion rates in the US were substantial in 2022, with prevalence and disparities varying by sex, race and ethnicity, and region.

jamanetwork.com/journals/jam...

An infographic that summarizes the main findings of a study titled "Comparative efficacy of aflibercept, bevacizumab, and ranibizumab on hard exudate resolution in diabetic macular edema" from the February 2026 issue of The Canadian Journal of Ophthalmology.

This month’s visual abstract summarizes a study that compares the efficacy of aflibercept, bevacizumab, and ranibizumab for resolution of diabetic macular edema-associated hard exudates (HEs).

bit.ly/cjo_comparin...

#Ophthalmology #Retina #DiabeticMacularEdema

The Unfinished Story: Analyzing Publication Rates in Diabetic Retinopathy and Diabetic Macular Edema Trials Before the COVID-19 Era (1972-2018).
Coppinger, Austin J et al.
Paper
Details
#DiabeticRetinopathy #DiabeticMacularEdema #ClinicalTrialsResearch

Correlation of point-wise retinal sensitivity with localized features of diabetic macular edema using deep learning To evaluate the association between localized features of diabetic macular edema (DME) and point-wise retinal sensitivity (RS) assessed with microperimetry (MP) using deep learning (DL)-based automate...

This study evaluates the association between localized features of diabetic macular edema (DME) and point-wise retinal sensitivity (RS) assessed with microperimetry using deep learning based automated quantification on OCT scans.

bit.ly/cjo_retinal-...

#Ophthalmology #DiabeticMacularEdema #Retina

Foselutoclax Delivers Durable Vision Benefits in Diabetic Macular Edema - Ophthalmology Advisor Presenters at the AAO discussed phase 2 clinical trial results evaluating the safety and efficacy of foselutoclax (UBX1325) compared with aflibercept in diabetic macular edema.

#AAO2025: #Foselutoclax can improve best-corrected visual acuities in patients with #DiabeticMacularEdema and #VisualAcuity deficits, despite prior #AntiVEGF treatment. Presented at AAO 2025 by David Eichenbaum, MD, of Retina Vitreous Associates of Florida.

Read more ➡️: bit.ly/4nd34Xa

Genentech, a member of the Roche Group, announced the FDA approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of DME. Susvimo is now available to US retina specialists+their patients with DME. ophthalmologymanagement.com/news/2025/fd... #diabeticmacularedema #dme #retina

Preparing for bilateral eye injections.

#eyelea #diabeticmacularedema #diabeticretinopathy